EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Rodrigo Jiménez-Saiz iD, Salvador Iborra iD, Carlos Blanco iD, Ruperto González-Pérez iD, Emilio Nuñez-Borque iD, Can Zeyneloglu iD, Huseyn Babayev iD, Ozlem Göksel iD, Tuncay Göksel iD, Musa Khaitov iD, Dmitry Kudlay iD, Yadong Gao iD und 11 weitere

Allergy · 2026-11 · 81 (11) · 3825-3852

DOI: 10.1111/all.70512 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 09.09.2026. Verfasst von Rodrigo Jiménez-Saiz und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain. Hauptthemen laut MEDLINE: Hypersensitivity, Th2 Cells, Immunity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 297 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (MICIU), Fundación Domingo Martínez.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue protection and repair. There are major clues from the early evolution of T2 responses for protection against massive tissue damage and positive selection for survival against parasites starting over 500 million years ago. These responses likely co‐evolved stepwise with immune‐regulatory circuits, culminating in the emergence of the fully functional human‐type IgG4 in the great apes (Hominidae) within the last ~10 million years. The involvement of body barriers along with the strong influence of local epithelial cells and their interaction with the microbiome and the immune system is a common characteristic of T2 inflammation. An expanding list of new T2 diseases is being reported, characterized by epithelial cell and immune system activation, epithelial barrier damage, and microbial dysbiosis, including opportunistic pathogen colonization and loss of commensals. This evolving understanding coincides with the clinical success of biologics targeting key T2 mediators such as IL‐4, IL‐5, IL‐13, IL‐31, TSLP, and IgE, which have transformed the management of severe allergic diseases and other T2‐driven pathologies. However, the contribution of T2 immunity to homeostatic programs raises questions about the long‐term consequences of sustained T2 suppression. In this review, we examine the dual role of T2 immunity in health and disease, revisit its evolutionary origins, highlight its protective functions beyond allergy, and discuss the potential implications of prolonged T2 pathway blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypersensitivityTh2 CellsImmunityHumansAnimalsDisease SusceptibilityCytokines

Stichwörter der Autor:innen

Type 2 immunityallergybiologicshomeostasisinflammation

Substanzen

Cytokines

Autor:innen und Institutionen

  • Department of Immunology, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain.
  • Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.
  • Department of Medicine, McMaster Immunology Research Centre (MIRC), Schroeder Allergy and Immunology Research Institute (SAIRI), McMaster University, Hamilton, Canada.
  • Fundación Inmunotek, Alcalá de Henares, Spain.
  • Department of Allergy, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.
  • Department of Allergy, Hospital Universitario de Canarias (HUC), Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain.

ORCID-Profile: Rodrigo Jiménez-Saiz, Salvador Iborra, Carlos Blanco, Ruperto González-Pérez, Emilio Nuñez-Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie-Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J Torres, Mohamed Shamji, Mübeccel Akdis, Kari C Nadeau, Ismail Ogulur, Cezmi A Akdis

Förderung

  • Instituto de Salud Carlos III (ISCIII)
  • Ministerio de Ciencia, Innovación y Universidades (MICIU)
  • Fundación Domingo Martínez
  • Weston Family Foundation
  • Comunidad de Madrid
  • IIS-Princesa
  • Sociedad Española de Alergología e Inmunología Clínica (SEAIC)
  • BBVA Foundation

Zitieren

APA

Jiménez-Saiz, R., Iborra, S., Blanco, C., González-Pérez, R., Nuñez-Borque, E., Zeyneloglu, C., Babayev, H., Göksel, O., Göksel, T., Khaitov, M., Kudlay, D., Gao, Y., Sevim, M., Brüggen, M. C., Alpan, O., Wang, M., Zhang, L., Torres, M. J., Shamji, M., …, & Akdis, C. A. (2026). Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases. Allergy, 81(11), 3825-3852. https://doi.org/10.1111/all.70512

Vancouver

Jiménez-Saiz R, Iborra S, Blanco C, González-Pérez R, Nuñez-Borque E, Zeyneloglu C, et al. Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases. Allergy. 2026;81(11):3825-3852. doi:10.1111/all.70512

BibTeX
@article{JimnezSaiz2026,
  author = {Jiménez-Saiz, Rodrigo and Iborra, Salvador and Blanco, Carlos and González-Pérez, Ruperto and Nuñez-Borque, Emilio and Zeyneloglu, Can and Babayev, Huseyn and Göksel, Ozlem and Göksel, Tuncay and Khaitov, Musa and Kudlay, Dmitry and Gao, Yadong and Sevim, Mustafa and Brüggen, Marie-Charlotte and Alpan, Oral and Wang, Ming and Zhang, Luo and Torres, María J and Shamji, Mohamed and Akdis, Mübeccel and Nadeau, Kari C and Ogulur, Ismail and Akdis, Cezmi A},
  title = {Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {11},
  pages = {3825--3852},
  doi = {10.1111/all.70512}
}
Kostenlos starten →